Advertisement
U.S. markets closed
  • S&P Futures

    4,568.25
    -8.25 (-0.18%)
     
  • Dow Futures

    36,211.00
    -57.00 (-0.16%)
     
  • Nasdaq Futures

    15,842.25
    -26.75 (-0.17%)
     
  • Russell 2000 Futures

    1,881.30
    -3.60 (-0.19%)
     
  • Crude Oil

    73.18
    +0.14 (+0.19%)
     
  • Gold

    2,054.00
    +11.80 (+0.58%)
     
  • Silver

    24.93
    +0.03 (+0.11%)
     
  • EUR/USD

    1.0844
    +0.0007 (+0.07%)
     
  • 10-Yr Bond

    4.2880
    +0.0620 (+1.47%)
     
  • Vix

    13.08
    +0.45 (+3.56%)
     
  • GBP/USD

    1.2638
    +0.0006 (+0.04%)
     
  • USD/JPY

    147.1040
    -0.0530 (-0.04%)
     
  • Bitcoin USD

    41,734.16
    +1,179.78 (+2.91%)
     
  • CMC Crypto 200

    859.41
    +0.70 (+0.08%)
     
  • FTSE 100

    7,512.96
    -16.39 (-0.22%)
     
  • Nikkei 225

    32,784.96
    -446.31 (-1.34%)
     

Ionis to present at upcoming investor conferences

CARLSBAD, Calif., Aug. 30, 2023  /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)
(PRNewsfoto/Ionis Pharmaceuticals, Inc.)
  • 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023

  • Citi's 18th Annual BioPharma Conference on Thursday, September 7, 2023

  • Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301912983.html

SOURCE Ionis Pharmaceuticals, Inc.

Advertisement